REGN Regeneron Pharmaceuticals, Inc.

NASDAQ
$734.81

Regeneron Pharmaceuticals, Inc. (REGN) is confirmed to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is $13.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.7% since its last earnings release on July 30, 2026.

Regeneron Pharmaceuticals Beat Expectations
Thursday, July 30, 2026 · 6:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 30
Friday · 6:30 AM ET
Earnings Whisper
-
vs $13.55 (GAAP)
Rev est $4.43B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $791.32

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Sector

Healthcare

Industry

Biotechnology

Held By 8 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.